A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImmunoGen, Inc.
• Treatments: Ado-trastuzumab emtansine; Carboplatin; Etoposide; Etoposide phosphate; Lorvotuzumab mertansine; Maytansine

Criteria

Inclusion Criteria:

• Patients must be 18 years old

• Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease

• ECOG performance status of 0, 1, or 2

• No prior systemic chemotherapy for the treatment of SCLC

Exclusion Criteria:

• Pregnant or lactating females